Analyzing Lombard Medical (OTCMKTS:EVARF) and NeuroPace (NASDAQ:NPCE)

Lombard Medical (OTCMKTS:EVARF) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Profitability

This table compares Lombard Medical and NeuroPace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lombard Medical	N/A	N/A	N/A
NeuroPace	-29.29%	-168.61%	-25.48%

Valuation and Earnings

This table compares Lombard Medical and NeuroPace”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lombard Medical	N/A	N/A	N/A	N/A	N/A
NeuroPace	$79.91 million	4.23	-$27.14 million	($0.84)	-12.17

Lombard Medical has higher earnings, but lower revenue than NeuroPace.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lombard Medical and NeuroPace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lombard Medical	0	0	0	0	0.00
NeuroPace	0	1	5	0	2.83

NeuroPace has a consensus price target of $16.60, suggesting a potential upside of 62.43%. Given NeuroPace’s stronger consensus rating and higher possible upside, analysts clearly believe NeuroPace is more favorable than Lombard Medical.

Institutional & Insider Ownership

78.8% of NeuroPace shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

NeuroPace beats Lombard Medical on 6 of the 9 factors compared between the two stocks.

About Lombard Medical

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.